Luigi Dolcetti
Overview
Explore the profile of Luigi Dolcetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deng J, Pan T, Wang D, Hong Y, Liu Z, Zhou X, et al.
EMBO Mol Med
. 2024 Aug;
16(9):2080-2108.
PMID: 39103698
Chemotherapy, the standard of care treatment for cancer patients with advanced disease, has been increasingly recognized to activate host immune responses to produce durable outcomes. Here, in colorectal adenocarcinoma (CRC)...
2.
Mancino C, Pasto A, De Rosa E, Dolcetti L, Rasponi M, McCulloch P, et al.
Heliyon
. 2023 Jun;
9(6):e16640.
PMID: 37313169
Post-traumatic osteoarthritis (PTOA) is one of the leading causes of disability in developed countries and accounts for 12% of all osteoarthritis cases in the United States. After trauma, inflammatory cells...
3.
Barber P, Mustapha R, Flores-Borja F, Alfano G, Ng K, Weitsman G, et al.
Elife
. 2022 Dec;
11.
PMID: 36562609
Background: Advanced head and neck squamous cell carcinoma (HNSCC) is associated with a poor prognosis, and biomarkers that predict response to treatment are highly desirable. The primary aim was to...
4.
Moise S, Dolcetti L, Dazzi F, Roach P, Buttery L, MacNeil S, et al.
Artif Cells Nanomed Biotechnol
. 2022 Jun;
50(1):168-176.
PMID: 35726746
Mesenchymal stromal cells (MSCs) show immunosuppressive effects both cell-to-cell contact (direct) with immune cells and by producing paracrine factors and extracellular vesicles (indirect). A key challenge in delivering this therapeutic...
5.
Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung T, et al.
Sci Transl Med
. 2017 Nov;
9(416).
PMID: 29141887
The immunosuppressive activity of mesenchymal stromal cells (MSCs) is well documented. However, the therapeutic benefit is completely unpredictable, thus raising concerns about MSC efficacy. One of the affecting factors is...
6.
Trento C, Marigo I, Pievani A, Galleu A, Dolcetti L, Wang C, et al.
Haematologica
. 2017 Feb;
102(5):818-825.
PMID: 28183849
Bone marrow microenvironment is fundamental for hematopoietic homeostasis. Numerous efforts have been made to reproduce or manipulate its activity to facilitate engraftment after hematopoietic stem cell transplantation but clinical results...
7.
Fernandez A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, et al.
J Immunol
. 2010 Dec;
186(1):264-74.
PMID: 21135171
The interaction between cancer vaccine adjuvants and myeloid-derived suppressor cells (MDSCs) is currently poorly understood. Very small size proteoliposomes (VSSP) are a nanoparticulated adjuvant under investigation in clinical trials in...
8.
Dolcetti L, Peranzoni E, Bronte V
Curr Protoc Immunol
. 2010 Nov;
Chapter 14:Unit 14.17.
PMID: 21053303
This unit presents simple methods to assess the immunosuppressive properties of immunoregulatory cells of myeloid origin, such as myeloid-derived suppressor cells (MDSCs), both in vitro and in vivo. These methods...
9.
Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al.
Immunity
. 2010 Jul;
32(6):790-802.
PMID: 20605485
Tumor growth is associated with a profound alteration in myelopoiesis, leading to recruitment of immunosuppressive cells known as myeloid-derived suppressor cells (MDSCs). We showed that among factors produced by various...
10.
Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al.
Curr Opin Immunol
. 2010 Feb;
22(2):238-44.
PMID: 20171075
Myeloid derived suppressor cells (MDSCs) are defined in mice on the basis of CD11b and Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. Nevertheless the term...